Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
| Image |  |
|---|---|
| Description | scientific article published in March 2011 |
| Author/s |
author: Michael Donohue Paul S. Aisen |
| Publication date | March 1, 2011 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |